Press release
Announce Strategic Partnership to Enhance Access to High-Quality Antibodies
Cambridge - August 28th 2025 - Antibodies.com, a trusted provider of high-quality antibodies and research reagents, is proud to announce a strategic partnership with Carl Roth, a leading supplier of laboratory and research chemicals. This collaboration represents an important milestone, expanding access to Antibodies.com's cutting-edge portfolio for Carl Roth's customers across Europe.Through this partnership, Carl Roth will distribute Antibodies.com's extensive collection of antibodies and immunoassays - including monoclonal, polyclonal, and recombinant products - designed to meet the needs of researchers in academia, biotechnology, and the pharmaceutical industry. With a strong reputation for quality, reliability, and affordability, Antibodies.com complements Carl Roth's mission to deliver best-in-class solutions for scientific discovery.
"We are excited to partner with Carl Roth, a company that shares our dedication to advancing scientific research," said Sebastian Newlove, Co-Founder of Antibodies.com. "Together, we aim to make high-quality antibodies more accessible, enabling researchers to achieve their goals with confidence and efficiency."
Dr. Leonie Hacker, Head of Product Management Chemistry & Life Science at Carl Roth, added: "This partnership represents a significant step forward in our commitment to empowering researchers with the best tools available. By integrating Antibodies.com's high-quality antibodies into our offerings, we are ensuring that our customers have access to innovative products at fair prices, supporting their groundbreaking work in life sciences."
Antibodies.com's customer-focused approach - emphasising transparency, rigorous quality control, and exceptional value - combined with Carl Roth's established distribution network, will streamline access to these products, ensuring seamless delivery and support for researchers across Europe.
This collaboration underscores the shared vision of both companies: to foster innovation and excellence within the scientific community. Researchers can now explore Antibodies.com's antibody portfolio through Carl Roth's online platform or by contacting their sales representatives for tailored support.
For more information about this partnership or to browse the expanded product offerings, visit www.antibodies.com [http://www.antibodies.com/?utm_source=chatgpt.com] or www.carlroth.com [http://www.carlroth.com/?utm_source=chatgpt.com].
About Carl Roth
Carl Roth, headquartered in Karlsruhe, Germany, is a leading distributor of laboratory supplies, chemicals, and equipment. With a legacy of excellence spanning decades, Carl Roth serves researchers and professionals in life sciences, chemistry, and beyond, delivering high-quality products and exceptional customer service.
About Antibodies.com
Antibodies.com is a global provider of high-quality antibodies and research reagents, dedicated to supporting scientific discovery. With a focus on affordability, reliability, and innovation, Antibodies.com empowers researchers with the tools they need to advance their work in immunology, oncology, and other critical fields.
Media Contact
Company Name: antibodies.com
Contact Person: Christian Lautenschlager
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=announce-strategic-partnership-to-enhance-access-to-highquality-antibodies]
Phone: + 44 (0)1223 298 875
Country: United Kingdom
Website: http://Antibodies.com
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Announce Strategic Partnership to Enhance Access to High-Quality Antibodies here
News-ID: 4162789 • Views: …
More Releases from ABNewswire

How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg
Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject.
Essential Platform Features for Effective Online Chemistry Tutoring
Modern chemistry tutoring…

Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…

Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical De …
DelveInsight's, "Diabetic Retinopathy Pipeline Insights 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by…

Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
More Releases for Antibodies
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Arthritis Monoclonal Antibodies Market Report 2024 - Arthritis Monoclonal Antibo …
"The Business Research Company recently released a comprehensive report on the Global Arthritis Monoclonal Antibodies Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The arthritis monoclonal antibodies…
Global Multispecific Antibodies Market Size Antibodies Sales Forecast 2029
Global Multispecific Antibodies Market, Drug Sales, Price & Clinical Trials Insight 2029 Report Highlights:
• Global & Regional Market Analysis
• Global Multispecific Antibodies Market Opportunity: > USD 40 Billion
• Global Multispecific Antibodies Market Sales In 2023: > USD 8 Billion
• Number Of Approved Multispecific Antibodies: 14
• Approved Antibodies Global, Regional, Annual & Quarterly Sales Insight
• Approved Antibodies Dosage & Pricing Insight
• Number Of Multispecific Antibodies: In Clinical Trials: > 900
• Comprehensive Insight On All Antibodies In Clinical Trials By…
Global Bispecific Antibody Market Size Bispecific Antibodies Clinical Trials FDA …
Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report Highlights:
• Bispecific Antibodies Development Proprietary Platforms Insight: > 30 Platforms
• Global Bispecific Antibodies Market Size Yearly and Quarterly Sales (2018 till 2023)
• Global Bispecific Antibodies Market Size 2023: > USD 8 Billion
• Global Bispecific Antibodies Market Forecast Till 2029
• Approved Bispecific Antibodies Yearly and Quarterly Sales (2018 till 2023)
• Approved Bispecific Antibodies Regional Sales (2018 till 2023)
• Clinical and Commercial Insight On Approved…
Emergence of Tetravalent Antibodies
The emergence of tetravalent antibodies represents a significant advancement in the field of therapeutic antibodies, offering new possibilities for treating complex diseases such as cancer, infectious diseases, and autoimmune disorders. These innovative molecules, capable of binding to four antigens or epitopes simultaneously, provide enhanced specificity, efficacy, and versatility, addressing the limitations of traditional monoclonal and even bispecific antibodies.
Download Bispecific, Trispecific and Tetraspecific Antibodies Report:
https://www.kuickresearch.com/ccformF.php?t=1721642510
Tetravalent antibodies are designed to engage…